SCHEMBL14820301

SCHEMBL14820301

CSc1ccc2c(N3CC(N)C3)ncnc2c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ PDGFRB P09619 2/20 0.40
▸ DOT1L Q8TEK3 1/20 0.40
▸ PRKDC P78527 7/20 0.39
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ KIT P10721 1/20 0.37
▸ AKT2 P31751 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ SUV39H1 O43463 2/20 0.37
▸ PRMT1 Q99873 2/20 0.37
▸ SMYD3 Q9H7B4 2/20 0.37
▸ HRH4 Q9H3N8 1/20 0.37
▸ GAK O14976 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ ENPP1 P22413 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14820079 0.87 CYP1A2 (0.41) CYP1A2CYP2D6PDGFRBPRKDCLMNA
SCHEMBL18485270 0.86 CYP1A2 (0.43) CYP1A2CYP2D6DOT1LPRKDCLMNA
SCHEMBL14805698 0.86 CYP1A2 (0.41) CYP1A2CYP2D6DOT1LPRKDCLMNA
SCHEMBL18485223 0.86 CYP1A2 (0.38) CYP1A2CYP2D6DOT1LPRKDCLMNA
SCHEMBL14820275 0.78 KIT (0.55) PDGFRBPRKDCKITGAKPDE10A
SCHEMBL14805745 0.77 CYP1A2 (0.46) CYP1A2CYP2D6DOT1LPRKDCLMNA
SCHEMBL14820092 0.75 KIT (0.42) CYP1A2CYP2D6PDGFRBPRKDCKIT
SCHEMBL18484224 0.75 CYP1A2 (0.41) CYP1A2CYP2D6DOT1LPRKDCLMNA
SCHEMBL18484222 0.74 CYP1A2 (0.39) CYP1A2CYP2D6PRKDCLMNAHTT
SCHEMBL14805746 0.74 CYP1A2 (0.42) CYP1A2CYP2D6PRKDCLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037059-A1 GYRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-02-09 — — US disclosed
US-9481675-B2 Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-01 — — US disclosed
US-20130079323-A1 GYRASE INHIBITORS TRIUS THERAPEUTICS, INC. (US) 2013-03-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037059-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B CYP1A2 571/4885CYP2D6 263/4885PDGFRB 3757/4885
US-20130079323-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B CYP1A2 571/4885CYP2D6 263/4885PDGFRB 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback